Crossmark

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study

Crossref DOI link: https://doi.org/10.1038/s41392-024-02064-z

Published Online: 2024-12-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Hongkai

Jiang, Shusuan

Luo, Hong

Zhou, Fangjian

He, Dalin

Ma, Lulin

Guo, Hongqian

Liang, Chaozhao

Chong, Tie

Jiang, Jun

Chen, Zhiwen

Wang, Yong

Zou, Qing

Tian, Ye

Xiao, Jun

Huang, Jian

Chen, Jinchao

Dong, Qiang

Zhang, Xiaoping

Li, Hanzhong

Yang, Xinfeng

Lian, Jianpo

Wang, Wenliang

Ye, Dingwei
Funding

Funding for this research was provided by:

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
License Information

Text and Data Mining valid from 2024-12-18

Version of Record valid from 2024-12-18
More Information

Article History

Received: 5 June 2024

Revised: 10 October 2024

Accepted: 13 November 2024

First Online: 18 December 2024

Competing interests

: X.Y., J.L., and W.W. are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. The remaining co-authors declare no competing interests.

Document is current

Any future updates will be listed below